Seated systolic and diastolic BPs were measured using a mercury sphygmomanometer according to the American Heart Association and the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). 13, 14 Up to 3 measurements were averaged for systolic and diastolic pressures. Patients were considered hypertensive if they reported physician diagnosis of hypertension, current BP-reducing medication use, or had systolic BP ≥140 mm Hg and diastolic BP ≥90 mm Hg based on JNC 7 criteria.
T obacco smoking is the largest preventable risk factor for cardiovascular diseases (CVDs). [1] [2] [3] Hypertension is a major public health problem affecting ≈31.3% of US adults and a wellrecognized risk factor for CVD, end-stage renal disease, and increased mortality. 4 Several studies have reported an association between smoking and hypertension among smokers. [5] [6] [7] However, among never smokers, it is not clear whether exposure to secondhand smoke (SHS) is a risk for increased blood pressure (BP). There are only few studies investigating the relationship between SHS and increased BP in never smokers, and all of these studies used self-reported exposure to SHS, which is prone to misclassification bias. 8, 9 Cotinine is the principal metabolite of nicotine in the body. 10 Cotinine has been effectively used as a biomarker for exposure to tobacco, both active and secondhand tobacco smoke. 10 In this context, we examined the association between SHS exposure measured objectively by serum cotinine level and high BP among never smokers in a nationally representative sample of US adults, after adjusting for age, sex, race-ethnicity, body mass index, and other potential confounders.
Methods
The data for this study are derived from the National Health and Nutrition Examination Survey (NHANES) [2005] [2006] [2007] [2008] . Detailed description of NHANES study design and methods is available elsewhere. 11, 12 The NHANES included a stratified multistage probability sample representative of the civilian noninstitutionalized US population. Selection was based on counties, blocks, households, and individuals within households and included oversampling of non-Hispanic blacks and Mexican Americans to provide stable estimates of these groups. Of the 20 497 participants in NHANES 2005-2008, there were 10 914 who were ≥20 years of age. We further excluded participants who were pregnant (n=393), had prevalent CVD (n=1275), former and current smokers (n=4264), or those who were missing information on serum cotinine level (n=1556), systolic BP, diastolic BP (n=279), or other covariates (n=258) included in the multivariable model. This resulted in 2889 participants included in the final analysis.
Exposure Measurements
Serum specimens were processed, stored, and shipped to the Division of Environmental Health Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention for analysis. Detailed specimen collection and processing instructions were discussed in the NHANES Laboratory/Medical Technologists Procedures Manual.
11 Serum cotinine was measured by an isotope dilution-high-performance liquid chromatography atmospheric pressure chemical ionization-tandem mass spectrometry. Briefly, the serum sample was spiked with methyl-D3 cotinine as an internal standard, and after an equilibration period, the sample was applied to a basified solid-phase extraction column. Cotinine was extracted off the column with methylene chloride, the organic extract was concentrated, and the residue was injected onto a short, C18 high-performance liquid chromatography column. The eluant from these injections was monitored by atmospheric pressure chemical ionization-tandem mass spectrometry, and the m/z 80 daughter ion from the m/z 177 quasimolecular ion was quantitated, along with additional ions for the internal standard, external standard, and for confirmation. Cotinine concentrations were derived from the ratio of native/labeled cotinine in the sample, by comparisons to a standard curve. Detailed description of serum cotinine measurement in NHANES is available online. 12 Serum total cholesterol was measured enzymatically. Glycosylated hemoglobin measurements were performed on the Tosoh 2. Information on age, sex, race/ethnicity, alcohol intake, income, level of education, female hormone use, and cigarette smoking were obtained during a standardized questionnaire at home interview. Ratio of income/poverty was used as a measure of poverty. The Department of Health and Human Services poverty guidelines were used as the poverty measure to calculate this index. Poverty status was categorized into living below the federal poverty level (<1.00) and living at or above the federal poverty level (≥1.00). Educational attainment was categorized into less than high school graduate, high school graduate, and more than high school graduate. Hormone use was defined as females who ever used estrogen or progesterone for purposes other than birth control or fertility. Smoking status was categorized into never smokers (smoked <100 cigarettes during their lifetime), former smokers (smoked ≈100 cigarettes lifetime and currently not smoking), and current smokers (smoked ≈100 cigarettes lifetime and currently smoking). Alcohol drinking was categorized into never drinker, former drinker, moderate drinker (2 drinks per day), and heavy drinker (≥3 drinks per day). Information on anthropometric, physical, and laboratory components were obtained during the medical examination center assessment. Body mass index was calculated as weight in kilograms divided by height in meter squared.
Statistical Analysis
Serum cotinine level was analyzed both as a continuous and as a categorical variable. For analysis as a continuous variable, serum cotinine level was log-transformed as a result of their skewed distribution. We ran linear regression models to calculate the mean change in systolic and diastolic BPs separately, for each unit increase in log serum cotinine. We categorized serum cotinine level into quartiles. We ran linear regression models to calculate the mean change in systolic and diastolic BPs for each higher serum cotinine level by taking the lowest category as the referent. We additionally ran logistic regression models to calculate the odds ratio (odds ratio and 95% confidence interval [CI]) of hypertension for each higher serum cotinine level by taking the lowest category as the referent. We ran 2 nested models, the age, sex-adjusted model and the multivariable-adjusted model, additionally adjusting for ethnicity (non-Hispanic white, non-Hispanic black, all others), alcohol drinking (never drinker, former drinker, 1 drink per day, 2 drinks per day, ≥3 drinks per day), education (less than high school, high school, more than high school), poverty (living below the federal poverty level, living at or above the federal poverty level), ever used female hormones (yes, no), body mass index (normal weight, overweight, obese), glycosylated hemoglobin (%), and total cholesterol (in mg/dL). Trends in the odds ratio of mean change in systolic and diastolic BPs and hypertension across increasing serum cotinine levels were determined by modeling serum cotinine categories as an ordinal variable. Sample weights that account for the unequal probabilities of selection, oversampling, and nonresponse in the NHANES were applied for all analyses. Analyses were conducted using SAS (version 9.2, SAS Institute, Cary, NC) software. SEs were estimated using the Taylor series linearization method. Table 1 presents the baseline characteristics of the study population, all of whom were never smokers. Among 2889 participants included in the study, ≈53% were women and 64% were non-Hispanic white. Obese participants were 35% of the study population. Hypertension was present in 30.4% of the study population. The geometric mean of serum cotinine level was 0.10±0.01 ng/mL. Table 2 presents the association between serum cotinine as a continuous variable and systolic and diastolic BPs separately. 
Results
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Serum cotinine was positively associated with systolic BP in the age, sex-adjusted model and the multivariable model. In contrast, there was no association between serum cotinine (as a continuous variable) and diastolic BP. Table 3 presents the association between increasing quartiles of serum cotinine and mean change in systolic and diastolic BPs, taking the lowest quartile of serum cotinine as the referent category. Higher levels of serum cotinine were found to be positively associated with higher mean change in systolic BP in the age, sex-adjusted model and the multivariable-adjusted model. Tests for linear trends in were statistically significant. In contrast, there was no association between increasing quartiles of serum cotinine and diastolic BP. Table 4 presents the association between increasing quartiles of serum cotinine and hypertension. Increasing levels of serum cotinine were found to be associated with higher odds of hypertension in the age, sex-adjusted model and the multivariable model. Tests for linear trends for this association were also statistically significant. We performed a supplementary analysis where we confined the analysis to self-reported never smokers with serum cotinine levels <10 ng/mL; the results in this subgroup of low serum cotinine subjects were similar to our main findings in Table 2 .
Discussion
Among never smokers in a representative sample of the US general population, we found that higher levels of serum cotinine, an objective marker of SHS exposure, were positively associated with higher systolic BP independent of age, sex, ethnicity, education categories, drinking, body mass index, glycohemoglobin, total cholesterol, poverty level, and hormone use. However, there was no positive association between serum cotinine and diastolic BP. In addition, higher levels of serum cotinine were positively associated with hypertension, defined as self-reported physician diagnosis of hypertension; current BP-reducing medication use; or systolic BP ≥140 mm Hg and diastolic BP ≥90 mm Hg.
Several previous studies have reported a positive association between smoking and hypertension. [15] [16] [17] [18] [19] There are few studies investigating the relationship between SHS exposure and BP among never smokers. A cross-sectional study involving clinically normotensive passive smokers found that selfreported passive smoking was associated with increased levels of BP in a dose-related manner. 9 In another study of 30 healthy nonsmoking women, systolic and diastolic BPs were found to be acutely elevated after the exposure to passive smoking. 8 However, a limitation to these previous studies is that SHS exposure was assessed entirely on the basis of self-report and not using objective measures, which in turn may have resulted in exposure misclassification.
In the current study, serum cotinine level were used to measure the level of exposure to SHS among never smokers. BP indicates blood pressure; BMI, body mass index. *Adjusted for age (y), sex (men, women), ethnicity (non-Hispanic white, non-Hispanic black, all others), education categories (<high school, high school, >high school), drinking (never drinker, former drinker, 1 drink per day, 2 drinks per day, ≥3 drinks per day), BMI (normal weight, overweight, obese), glycohemoglobin (%), total cholesterol (mg/dL), below poverty level (%), and hormones (%). Table 3 BP indicates blood pressure; BMI, body mass index; CI, confidence interval. *Adjusted for age (y), sex (men, women), ethnicity (non-Hispanic white, non-Hispanic black, all others), education categories (<high school, high school, >high school), drinking (never drinker, former drinker, 1 drink per day, 2 drinks per day, ≥3 drinks per day), BMI (normal weight, overweight, obese), glycohemoglobin (%), total cholesterol (mg/dL), below poverty level (%), and hormones (%). Cotinine is the principal metabolite of nicotine and has a 15-40 hour half-life. 10 Serum cotinine is considered a more precise measure of exposure to cigarette smoking when compared with self-reported smoking status and is considered an accurate biomarker of SHS exposure. 10 The most widely cited serum cotinine cut point for discriminating smokers from nonsmokers is 14 ng/mL 20 ; therefore, on average, a never smoker living with a smoker may be expected to have levels below this cutoff. In the current study where we examined self-reported never smokers, the mean (SD) of serum cotinine was 0.1 (0.01), indicating a low level of exposure to SHS. In addition, we ran a supplementary analysis where we confined the analysis to never smokers with serum cotinine levels <10 ng/mL. The results in this subgroup of low serum cotinine subjects were similar to our main findings. Furthermore, the results from our multivariable linear regression analyses also indicated that a 0.01-ng/mL increase in serum cotinine in never smokers is independently associated with a 1-mm Hg increase in systolic BP.
The mechanisms underlying the observed association between SHS and hypertension in never smokers remain unknown. A vasoconstriction mediated by nicotine is initially responsible for acute but transient increase in the systolic BP. 21 This phase is followed by a decrease in BP as a consequence of nicotine depressant effects. In the long run, it has been suggested that carbon monoxide acts directly on the arterial wall potentially causing endothelial dysfunction [22] [23] [24] [25] and structurally irreversible alterations, such as arterial stiffness. 26 These changes potentially lead to a state of chronically elevated BP and hypertension. 27 In the current analysis, serum cotinine was positively associated with systolic BP; however, no similar association was found with diastolic BP. The biological mechanism underlying such difference is unclear. However, consistent with our findings, several studies measuring the association between exposure to environmental pollutants (other than SHS) and BP have reported increases in the systolic BP, with no similar increase in the diastolic BP. 28, 29 In addition, systolic BP has recently been shown to be more important than the diastolic BP in estimating the risk of CVD. 28 This study has numerous strengths. Ours is the first study to date investigating the relationship between nicotine exposure measured objectively by serum cotinine level and increased BP in never smokers. We believe that our use of serum cotinine will minimize the potential for misclassification bias. Moreover, the large national sample of racially and ethnically diverse US adults and the ability to adjust for numerous potential confounders add to the strengths of the study. The cross-sectional nature of NHANES represents the main limitation of the study because it does not allow us to draw conclusions regarding the causal role of nicotine exposure in hypertension. However, recent studies on the effect of smoking bans on CVD incidence suggest that reductions in risk may occur immediately with changes in exposure 30 ; hence, the concurrent exposure and outcome observed in this article may be of public health interest.
Perspectives
In a representative sample of US adults who were never smokers, we found that higher serum cotinine levels were associated with higher systolic BP and the presence of hypertension, independent of confounding factors. Prospective studies with larger sample sizes are necessary to confirm or refute our findings.
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